Pictet North America Advisors 13F: Adds $954K to DHR Stake
Key Points
- Pictet North America Advisors lifted its stake in Danaher Corporation by 51.3%, bringing its total share count to 12,704 shares valued at about $2.81 million in an October 21, 2026 filing.
- Danaher Corporation trades recently near $234.02, sitting about 3.6% below its 52-week high while generating $25.11 billion in trailing annual revenue.
- The medical and industrial products maker pays an annual dividend rate of $1.60 per share, yielding 0.71% with a payout ratio of 25.7%.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Pictet North America Advisors increased its investment in Danaher Corporation DHR, adding 4,305 shares during the quarter. According to a Form 13F filed with the U.S. Securities and Exchange Commission on October 21, 2026, the firm's stake grew by 51.3% to reach 12,704 shares. The updated holding was valued at approximately $2.81 million at the end of the period.
DHR
Danaher Corporation
What Changed in Pictet North America Advisors's Danaher Position
The fund expanded its position from 8,399 shares previously to 12,704 shares. That 4,305-share increase bumped the total portfolio value of the holding up to $2,814,571.
Other Institutional Activity in Danaher
Other large institutional investors adjusted their positions in the medical and life sciences firm around the same period. Davenport grew its holdings by 122,935 shares, ending with 801,278 shares worth about $178.37 million. Robeco Institutional Asset Management B.V. cut its stake by 79.7%, reducing its holdings by 330,568 shares to finish with 84,148 shares valued at about $18.64 million. Montrusco Bolton Investments cut its position by 14.3%, dropping 152,432 shares to hold 912,150 shares worth roughly $202.09 million. Capital International Investors added 1,489,759 shares for a 10.6% increase, finishing with 15,504,420 shares valued at about $3.63 billion.
Danaher Corporation Stock Up 4.3%
Danaher shares closed at $233.86 on the filing date of October 21, 2026, and recently traded around $234.02 as of October 22, 2026. That recent price puts the stock up about 0.1% compared to that filing close. The shares sit 8.8% above their 50-day moving average of $215.12 and 16.3% above their 200-day moving average of $201.26. The stock trades about 3.6% below its 52-week high of $242.80 and 45.4% above its 52-week low of $160.93.
Recent Earnings
Danaher generated $25.11 billion in trailing-twelve-month revenue with earnings of $6.04 per share. The company posted a net profit margin of 15.9% and a return on equity of 7.6%, alongside a year-over-year revenue growth rate of 5.5%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60 per share, yielding 0.71%. The company distributes roughly 25.7% of its earnings as dividends, as indicated by its dividend payout ratio.
Insider Buying and Selling at Danaher Corporation
Company insiders also transacted in shares earlier in the year. Director Alan G. Spoon sold 1,358 shares on May 1, 2026, at an average price of $174.67 for a total value of $237,207. Chief Executive Officer Rainer M. Blair sold 58,255 shares on August 21, 2026, valued at approximately $12.74 million.
Analysts Set New Price Targets
Wall Street research firms updated their views on the stock through October. RBC Capital maintained its Outperform rating while raising its price target to $250.00 from $215.00 on October 5, 2026. Barclays maintained an Overweight rating and lifted its target to $255.00 from $230.00 on October 7, 2026. Morgan Stanley kept an Overweight rating and raised its target to $240.00 from $220.00 on October 13, 2026. TD Cowen maintained a Buy rating and pushed its target to $255.00 from $236.00 on October 13, 2026. Later, on October 22, 2026, JP Morgan maintained an Overweight rating with a $270.00 target. The stock carries a consensus rating of Strong Buy from 22 analysts, with a mean price target of $247.18.
About Danaher
Headquartered in Washington, DC, Danaher Corporation designs and manufactures medical, life sciences, and industrial tools and diagnostic systems. The company operates across biotechnology, diagnostics, and life sciences markets worldwide, supplying equipment and consumables used in research and healthcare.
Bottom Line
Institutional investors continue to adjust large positions in Danaher as the stock trades near its 52-week highs. Observers will monitor upcoming earnings reports and subsequent SEC filings to track how major funds manage their exposure.
Related Filing Alerts
Source: Pictet North America Advisors's 13F filing on $DHR (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts